You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 3, March 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Case Reports and Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lipemia Retinalis in Acquired Immunodeficiency Syndrome Treated With Protease Inhibitors

Arch Ophthalmol. 2000;118:425-426.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Report of a Case

A 39-year-old man with human immunodeficiency virus infection developed cytomegalovirus retinitis in the right eye in 1995, necessitating treatment with foscarnet sodium. His CD4 cell count was 0.01 x 109/L (10/µL). His medications included zidovudine, lamivudine, trimethoprim-sulfamethoxazole, rifabutin, and acyclovir. Indinavir sulfate was added to his drug regimen in 1996. He had no history of diabetes mellitus, hypertension, or coronary artery disease. Findings from an examination in September 1996 revealed a macula-off retinal detachment in the right eye secondary to inactive cytomegalovirus retinitis. He underwent an uncomplicated right vitrectomy and silicone oil insertion in February 1997. The retina was attached postoperatively with atrophic macular changes resulting in poor vision. Retinal blood vessels were normal bilaterally. Because of a slowly climbing viral load to 162,000 copies per milliliter, the patient's antiviral therapy was changed in December 1997 to zalcitabine, ritonavir, saquinavir mesylate, and delavirdine mesylate.

In March 1998, the patient's . . . [Full Text of this Article]


Comment
Kenneth T. Eng, MD; Eugene S. Liu, MD; Michael S. Silverman, MD, FRCPC; Alan R. Berger, MD, FRCSC
Toronto, Ontario

Corresponding author: Alan R. Berger, MD, FRCSC, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Suite M1-202A, Toronto, Ontario, Canada M4N 3M5.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.